Home » Stocks » IMCR

Immunocore Holdings Limited (IMCR)

Stock Price: $39.26 USD -1.71 (-4.17%)
Updated Jun 21, 2021 12:35 PM EDT - Market open
Market Cap 1.83B
Revenue (ttm) 30.13M
Net Income (ttm) n/a
Shares Out 43.79M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $39.26
Previous Close $40.97
Change ($) -1.71
Change (%) -4.17%
Day's Open 40.84
Day's Range 39.26 - 40.84
Day's Volume 7,079
52-Week Range 30.92 - 61.99


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation


3 weeks ago - GlobeNewsWire


1 month ago - GlobeNewsWire

Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.

Other stocks mentioned: AFRM, RBLX
1 month ago - The Motley Fool

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

2 months ago - GlobeNewsWire

Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary

3 months ago - GlobeNewsWire

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...

4 months ago - Benzinga

About IMCR

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disea... [Read more...]

IPO Date
Feb 5, 2021
Bahija Jallal, Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Immunocore is 51.50, which is an increase of 31.18% from the latest price.

Price Target
(31.18% upside)